Neferine increases STI571 chemosensitivity via inhibition of P-gp expression in STI571-resistant K562 cells. (Record no. 20542399)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 01506 a2200409 4500 |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20250516022017.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 201107s 0 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
International Standard Serial Number | 1029-2403 |
024 7# - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.3109/10428194.2010.550075 |
Source of number or code | doi |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | NLM |
Language of cataloging | eng |
Transcribing agency | NLM |
100 1# - MAIN ENTRY--PERSONAL NAME | |
Personal name | Qin, Qun |
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
Date of production, publication, distribution, manufacture, or copyright notice | 20110714 |
245 00 - TITLE STATEMENT | |
Title | Neferine increases STI571 chemosensitivity via inhibition of P-gp expression in STI571-resistant K562 cells. |
Medium | [electronic resource] |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Name of publisher, distributor, etc. | Leukemia & lymphoma |
Date of publication, distribution, etc. | Apr 2011 |
300 ## - PHYSICAL DESCRIPTION | |
Extent | 694-700 p. |
Other physical details | digital |
500 ## - GENERAL NOTE | |
General note | Publication Type: Journal Article; Research Support, Non-U.S. Gov't |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | ATP Binding Cassette Transporter, Subfamily B, Member 1 |
General subdivision | antagonists & inhibitors |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Benzamides |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Benzylisoquinolines |
General subdivision | pharmacology |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Cell Survival |
General subdivision | drug effects |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Drug Resistance, Neoplasm |
General subdivision | drug effects |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Drug Synergism |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Gene Expression Regulation, Leukemic |
General subdivision | drug effects |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Humans |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Imatinib Mesylate |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | K562 Cells |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Piperazines |
General subdivision | pharmacology |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Pyrimidines |
General subdivision | pharmacology |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | RNA, Messenger |
General subdivision | genetics |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Chen, Xiao-Ping |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Yang, Zhou-Sheng |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Xiao, Yu-Hang |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Min, Hui |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Li, Yuan-Jian |
773 0# - HOST ITEM ENTRY | |
Title | Leukemia & lymphoma |
Related parts | vol. 52 |
-- | no. 4 |
-- | p. 694-700 |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="https://doi.org/10.3109/10428194.2010.550075">https://doi.org/10.3109/10428194.2010.550075</a> |
Public note | Available from publisher's website |
No items available.